European Society for Medical Oncology (ESMO) Asia Congress 2022
Title | European Society for Medical Oncology (ESMO) Asia Congress 2022 |
---|---|
Description | Conclusions: NIVO + chemo did not show statistically significant improvement in PFS in pts with EGFR-mut mNSCLC after progression on EGFR TKIs; however, a trend of benefit was seen in pts with sensitizing EGFR mutations and in those with 1 prior line of EGFR TKI tx. No new safety signals were identified. |
Organism | Homo sapiens |
Data Type | Other Type of Metabolome Data |
Data Accessibility | Open-access |
BioProject | PRJCA012509 |
Release Date | 2022-10-18 |
Submitter | Qi Zhang (qi.zhang@ppd.com) |
Organization | Guangdong Provincial People's Hospital |
Submission Date | 2022-10-14 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
---|---|---|---|---|---|---|---|
OMIX002063-01 | Mok_ESMO Asia2022_CM722_Full abstract_SUBMITTED | 1 | Other Type of Metabolome Data | 101.3 KB | zip | 0 |